Abstract: Currently, a wide range of research involving natural products is focused on the discovery of new drugs in many different therapeutic areas. A great number of the synthetic compounds on the market were derived from natural products, especially plants. Nemorosone is the major constituent of the floral resin of Clusia rosea Jacq., Clusiaceae, and in Cuban propolis. In vitro studies have shown cytotoxic activity in this substance against various tumor cell lines, including those resistant to various cytotoxic drugs, whereas it has low cytotoxicity to non-tumoral cells. Therefore, in order to characterize the biological activity of nemorosone, a substance with potential antitumor activity, and in view of preclinical testing of the toxicity of drug candidate compounds, the main aim of this study was to determine the mutagenic and antimutagenic activity of nemorosone by the Ames test, using the strains TA97a, TA98, TA100 and TA102 of Salmonella typhimurium. Secondly, to characterize the estrogenic activity in an experimental recombinant yeast model (Recombinant Yeast Assay) mutagenic activity was observed at in any of the concentrations in any of the test strains. To evaluate the antimutagenic potential, direct and indirect mutagenic agents were used: 4 nitro-o-phenylenediamine (NPD), mitomycin C (MMC) and aflatoxin B1 (AFL). Nemorosone showed moderate antimutagenic activity (inhibition level 31%), in strain TA100 in the presence of AFL, and strong antimutagenic activity in TA102 against MMC (inhibition level 53%). Estrogenic activity was observed, with an EEq of 0.41±0.16 nM at various tested concentrations.
Introduction
Nemorosone is found in the resin and latex of plants of Clusia (fam. Clusiaceae, syn. Guttiferae) species (Lokvam et al., 2000) and it is the major constituent of Clusia rosea Jacq. floral resins (CuestaRubio et al., 2001; Popolo et al., 2011) and brown Cuban propolis (Cuesta-Rubio et al., 2002; Cuesta-Rubio et al., 2007; Pardo-Andreu et al., 2011) . This compound belongs to the class of polycyclic polyisoprenylated benzophenones, a group of acylphloroglucinol derivates wich are characteristic secondary metabolites of the Guttiferae family (Pagano et al., 2008) .
The cytotoxicity of nemorosone in several human cancer cell lines has been reported in the past years (Cuesta-Rubio et al., 2002; Diaz-Carballo et al., 2003; Popolo et al., 2011) . This compound showed cytotoxic activity in vitro against a range of tumor cell lines, such as breast, colon, ovary, liver and lung carcinoma (including both wild type and chemotherapyrefractory) and it presents low cytotoxicity against normal cell lines ( Diaz-Carballo, et al. 2003; DiazCarballo et al.,2008; Popolo et al., 2011) . The National Cancer Institute (USA), which considers that a pure compound is active when its IC50 is lower than 4 µg/ mL (Cordell et. al., 1993) ; nemorosone showed IC50 values lower than 3.6 µg/mL against several cancer cell lines (Cuesta-Rubio et al. 2001) .
Antineoplastic agents of plant origin, such as vinblastine, vinorelbine, etoposide, teniposide and others, are currently used as parts of anticancer treatment protocols (Bulanas & Kinghorn, 2005) . Phytochemicals have very good prospects as anticancer agents on account of their great chemical diversity and unlimited potential for rational modification (DiazCarballo et al., 2008) .
Compounds capable of provoking mutations are found in our daily diet, drinks and medication as well as in polluted air and water. It is known that mutations are a major factor for the onset of cancer. However, chemoprevention, that is the prevention of cancer development by chemical substances that act as antimutagenic agents, with the capacity to interact with mutagenic compounds or their metabolites and reduce their effects, is one possible way to prevent cancer (Nogueira et al., 2006; Lira et al., 2008; Chen et al., 2011) .
In recent years, endocrine disrupting chemicals (EDC) have become a major issue in the field of environmental science, owing to their ability to interact with human estrogen receptors, thus interfering with the endocrine system (Crews et al., 2000; Brix et al., 2010) . Epidemiological studies and animal experiments have shown that estrogen can have carcinogenic properties. Studies to clarify the molecular mechanisms of carcinogenesis by estrogen suggest that estrogen causes carcinogenic effects by combining genotoxicity and stimulation of cell proliferation (Bhat et al., 2003; Cavalieri et al., 2000) .
The main aim of this study was to assess the mutagenic and antimutagenic activity of nemorosone by the Salmonella reversion assay, which is widely used for the detection of mutagenic and antimutagenic agents, especially those present in plant extracts. To elucidate further the biological activity of this compound, its estrogenic activity was also tested by recombinant yeast assay.
Materials and Methods

Chemicals
Dimethylsulfoxide (DMSO), nicotinamide adenine dinucleotide phosphate sodium salt (NADP), D-glucose-6-phosphate disodium salt, magnesium chloride, L-histidine monohydrate, D-biotin, sodium azide (SAZ), 2-anthramine (2-ANTR), 4-nitro-ophenylenediamine (NPD), mitomycin C (MMC), aflatoxin B 1 (AFL), 17ß-estradiol, Triton X-100, SDS 10%, 2-mercaptoethanol, 4-methylumbelliferyl ß-Dgalactoside were purchased from Sigma Chemical Co (St. Louis, USA). Oxoid Nutrient Broth No. 2 (Oxoid, England) and Difco Bacto Agar (Difco, USA) were used as bacterial media.
Plant material
Flowers of Clusia rosea Jacq., Clusiaceae, were collected in Havana (Cuba) Nemorosone was extracted from the floral resins of C. rosea and isolated as previously reported (Cuesta-Rubio et al., 2001) In brief, nemorosone was crystallized from floral resins of Clusia rosea employing a mixture of EtOH-H 2 O. The product was subject to a VLC on silica gel with C 6 H 12 -EtOAc mixtures to purify it to homogeneity. It was identified through 1-D and 2-D NMR experiments, and its purity was verified by HPLC-DAD and HPLC-MS.
Ames mutagenicity assay
The Salmonella mutagenicity assay was performed by the pre-incubation method, for 20-30 min with Salmonella typhimurium strains, TA97a, TA98, TA100 and TA102, with and without metabolic activation (Maron & Ames, 1983) . The metabolic activation mixture (S9 mix) was freshly prepared before each test from an Aroclor-1254-induced rat liver fraction purchased (lyophilized) from Moltox Molecular Toxicology Inc. (Boone, NC). S. typhimurium strains were kindly provided by Dr. B. Ames, University of California, Berkeley, CA, USA. The benzophenone was diluted in dimethylsulfoxide and tested at concentrations of 5, 10, 20 and 30 µg/plate. The chosen sublethal concentrations were based on the toxicity of the benzophenone to the strains. Toxicity was apparent either as a reduction in the number of his + revertants, or as an alteration in the auxotrophic background. The various concentrations of nemorosone to be tested were added to 500 μL of buffer (pH 7.4) and 100 µL of S. typhimurium inoculum. After that, 2 mL of top agar was added to the mixture and poured on to a plate containing minimal agar. The plates were incubated at 37 °C for 48 h and the his + revertant colonies were counted manually. The influence of metabolic activation was tested by replacing the buffer with 500 µL of S9 mixture (4%). All experiments were performed in triplicate. The standard mutagens used as positive controls in experiments without S9 mix were 4-nitro-o-phenylenediamine (NPD-10 µg/plate) for TA98 and TA97a, sodium azide (2.5 µg/plate) for TA100 and daunomycin (3 µg/plate) for TA102, while 2-anthramine (0.63 µg/plate) was used in the experiments with metabolic activation for TA98, TA100 and TA97a and 2-aminofluorene (10 µg/ plate) for TA102.
The statistical analysis was performed with the Salanal computer program using the Bernstein model (Bernstein et al., 1982) . The data (revertants/plate) were assessed by analysis of variance (ANOVA), followed by linear regression. The mutagenic index (MI) was also calculated for each dose, as the average number of revertants per plate divided by average number of revertants per plate of the negative (solvent) control. A sample was considered positive when MI≥2 for at least one of the tested doses and if the response was dose dependent (Varella et al., 2004; Santos et al., 2010) .
Ames antimutagenicity assay
In accordance with the pre-incubation method, developed by Maron & Ames (1983) , various concentrations of nemorosone were mixed with 100 µL of S. typhimurium inoculum and the mutagenic agent (NPD, AFL or MMC), and incubated at 37 °C for 20-30 min. After this, 2 mL of top agar was added, supplemented with traces of histidine and biotin, and the content of each tube was lightly homogenized and poured onto a plate of minimal glucose agar. After the top agar solidification, the plates were incubated for 48 h at 37 °C, and the number of revertant colonies per plate was counted. The entire assay was performed in triplicate. The percentage of mutagenicity inhibition was calculated as in Tachino et al. (1994) , where:
The antimutagenic effect was considered negligible when a value lower than 25% was obtained, moderate when a value between 25% and 40% was obtained and strong at values greater than 40% (Neigi et al., 2003) .
Cell viability was also determined in each antimutagenesis experiment to assess the bactericidal potential of the mutagens. The responses were considered toxic when sample survival was less than 60% of the total observed for the negative control (Vargas et al., 1993) .
Recombinant yeast assay (RYA)
Yeast strain BY4741 (MATa ura3Δ0 leu2Δ0 his3Δ1 met15Δ0) from Euroscarf (Frankfurt, Germany) was transformed with plasmids pH5HE0 and pVitBX2, as described elsewhere (Garcia-Reyero et al., 2001) . Expression plasmid pH5HE0 contains the human estrogen hormone receptor HE0 (Green & Chambon, 1991) cloned into the constitutive yeast expression vector pAAH5. The reporter plasmid pVITB2x contains two copies of the pseudopalindromic estrogen responsive element ERE2 from X. laevis vitellogenin B1gene (5'AGTCACTGTGACC-3') inserted into the unique KpnI site of pSFLΔ-178k (Garcia-Reyero et al., 2005) . In brief, transformed yeast cells were first grown overnight in non-selective medium (YPD) at 30 °C. Next, they were grown overnight in minimal medium (6.7 g/L yeast nitrogen base without amino acids, Difco, Basel, Switzerland; 20 g/L glucose, supplemented with 0.1 g/L of prototrophic markers as required). The final culture was adjusted to an optical density (OD) of 0.1 and distributed in a siliconized 96-well polypropylene microtiter plate. Aliquots of 10 μL nemorosone solution at a final concentration giving 15 µg/well were added to 90 μL of yeast culture and these initial inoculum were used for subsequent serial dilutions (1:10, 1:30, 1:90, 1:270 and 1:810). Positive controls were made by adding 17ß-estradiol at a final concentration of 10 nM. For a toxicity control, 10 nM 17ß-estradiol was added to a sample with a dilution factor of 1:30. Plates were incubated for 6 h at 30 °C under mild shaking. After incubation, 50 μL of the yeast cells lysis reagent Y-PER TM (Pierce TM , Rockford, IL, USA) was added to each well and further incubated at 30 °C for 30 min. Finally, 50 μL of assay buffer was added to the lysed cells. The assay buffer was prepared by mixing 100 mL Z-buffer, 1 mL Triton X-100, 1 mL 10% SDS, 70 μL 2-mercaptoethanol and 21 mg 4-methyl umbelliferyl-ß-D-galactoside. Z-Buffer is a mix of: 60 mM Na2HPO4, 40 mM NaH 2 PO 4 , 10 mM KCl and 1 mM MgSO 4 , pH 7.0.
After brief centrifugation, plates were read in a spectrofluorometer (Tecan SpectraFluor Plus), set at 355 nm excitation and 460 nm emission. Fluorescence was recorded for 20 min (one measurement per min); ß-galactosidase activity was calculated as rate of the increase in arbitrary fluorescence units per min, using standard linear regression methods. Estrogenicity values are reported as nM concentration (in the sample) equivalent to 17ß-estradiol (EEQ). These values were calculated by adjusting ß-galactosidase values from serial dilutions of each sample to the Hill equation by nonlinear methods (Noguerol et al., 2006) . The entire assay was performed on four replicates.
Results and Discussion
The explosive growth of phytotherapy has created a new awareness of the potential value of natural products as anticancer agents (Diaz-Carballo et al., 2003) . It may be hoped that, if nemorosone can be developed into a clinical drug in the future, it would prove valuable in both first and second-line therapies (Diaz-Carballo et al., 2008) .
Tumor cells possess the characteristic of proliferating much faster than normal cells, so cell proliferation is used as one of the targets for the development of chemotherapeutic agents (Green et al., 2011) . These drugs however, when administered to patients, may kill normal cells and thus result in debilitating side effects (Keyomarsi & Pardee, 2003;  Most anti-tumoral agents are designed to action cell proliferation (Green et al., 2011) and apoptosis induction (Peng et al., 2003) . Drugs inhibit DNA synthesis by two mechanisms that are generally associated: the drug either binds to DNA by intercalation and stops the replication ; or interferes directly with molecules required for DNA polymerization and/or initiation of replication (Pommier et al., 1998; Bruning & Mylonas et al., 2011) . The ability of such drugs to intercalate into DNA can induce mutations in normal cells (Hoffmann et al., 2003) . The accumulation of several random mutations can lead to aberrations in the cells and conversion of non-carcinogenic cells into carcinogenic cells (Ferguson & Denny, 1995; Raynaud et al., 2008) . Thus it is essential that chemotherapeutic drugs be carefully tested not only for anticancer or antitumor activity, but also for their potential mutagenicity (Narayan et al., 2005) .
The Ames test is used worldwide as an initial screen to determine the mutagenic potential of new chemicals and drugs. The test is also used to furnish data for submission to regulatory agencies, for the registration or acceptance of many chemicals, including drugs and biocides. International guidelines have been developed for use by corporations and testing laboratories, to ensure uniformity of testing procedures (Mortelmans & Zeiger, 2000) .
In this study, the mutagenicity of nemorosone was assessed by the Ames test, using four different concentrations of the compound and four bacterial strains (Salmonella typhimurium TA97a, TA98, TA100 and TA102), each strain carrying different mutations in various genes in the histidine operon. A metabolic activation system (S9 mix) was added to S. typhimurium during the assay to metabolize the nemorosone by the cytocrome P450, enzymes extracted from rat liver. The results show that nemorosone did not induce any increase in the number of revertant colonies, indicating the absence of mutagenic activity. The results for mutagenic activity of nemorosone are presented in Table  1 , showing the number of revertants/plate, the standard deviation and the mutagenic index (MI) after treatment with this benzophenone. The mutagenic index (MI) was not higher than 2 at any tested concentration.
Given that oxidative stress is strongly implicated in the toxicity of chemotherapy, much effort has been focused on the research of diverse antioxidants as potential chemoprotective agents. Tzanova et al. (2009) demonstred the low toxicity of benzophenones to three cell lines and potent destruction of reactive oxygen species generated by tert-butyl hydroperoxide (tBHP). Interestingly, one of the investigated benzophenones was shown to protect non-cancerous cells against tBHP-induced death.
The antimutagenic activity of nemorosone was also assessed by the Ames test and the results are displayed in Table 2 . The benzophenone was tested in association with direct (NPD and MMC) and indirect mutagens (AFL) using strains TA98, TA102 and TA100, respectively. When strain TA98 was used in association with NPD was used, no reduction in the number of revertant colonies was observed. For strain TA100, a moderate protective effect was observed when tested with AFL (31% inhibition). However, in strain TA102, nemorosone showed a strong protective effect when tested with MMC (53% inhibition). Mitomycin C is a well known anti-tumor drug whose genotoxic effects in non-tumor cells are of special significance, owing to the possibility that it may induce secondary tumors in cancer patients (Aydemir et al., 2005) . It is quite possible that plants and their components may modulate the genotoxicity of anticancer drugs and thus may reduce the chances of cancer patients developing secondary tumors (Siddique et al., 2009 ). The present results show that nemorosone can reduce the mutagenic damage of one anti-cancer drug therapy (mitomycin C) reducing the probability of secondary tumors being induced in the cancerous patients treated with this drug. Table 1 . Mutagenic activity expressed as the mean and standard deviation of the number of revertants and mutagenic index (in brackets) in strains TA98, TA100, TA102 and TA97a exposed to nemorosone at various doses, with (+S9) or without (-S9) metabolic activation. These results shows that nemorosone, at various concentrations, has no estrogenic activity detectable by this method but does possesses a protective activity against some kinds of induced mutation.
Further studies should be performed to assess the biological activity of this benzophenone and clarify its mechanism of action. The possible health risks and benefits associated with the consumption of plant estrogens underline the need to characterize the estrogenic potency of vegetables and seeds commonly present in the diet or used as medicinal plants (Agradi at al., 2002) .
The estrogenic activity of nemorosone, evaluated by the recombinant yeast assay (RYA) based on vertebrate estrogen receptors, is a convenient measure of the potential for endocrine disruption of a substance or an environmental sample (Garcia-Reyero et al., 2005; Brix et al., 2010) . This assay makes use of an engineered yeast strain that harbors two foreign genetic elements: a vertebrate receptor, in this case, a human estrogen receptor, ER, and a reporter gene whose expression is made dependent on the presence of estrogens and whose final product concentration is easy to measure. This is a simplified version of the mechanism by which natural estrogens operate in vertebrates. The fundamental similarity of the transcriptional machinery in all eukaryotes ensures that it also works in yeast, in a similar way.
In breast carcinoma, the estrogen receptor (Erα) is present in 75% of cases (Popolo et al., 2011) . The phytoestrogens interact with these receptors inducing cancerous cell proliferation (Karayiannakis et al., 1996) . The estrogenicity of nemorosone was assessed at various concentrations (0.19-15 µg/well) by RYA and the compound exhibited 0.41nM±0.16 EEq. Figure 1 shows plots of the increase in fluorescence at in different concentrations of the benzophenone and methanol (negative control) against time (for 20 min). There are no significant differences between slopes of the nemorosone linear plots and the negative control. Figure 2 shows the mean β-galactosidase activity, in fluorescence units, induced by nemorosone and the negative control, plotted against dilution factor. Control+ -Positive Control: NPD -4-nitro-o-phenylenediamine (10μg/ plate)(-S9); Aflatoxin B1 (0.5 μg/plate) (+S9); Mitomycin C (0.5 μg/ plate)(-S9). 
